Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study.
Covid-19
Mortality
Vaccine effectiveness
Vaccines
Journal
Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
entrez:
6
7
2022
pubmed:
7
7
2022
medline:
7
7
2022
Statut:
ppublish
Résumé
In February 2021, Colombia began mass vaccination against COVID-19 using mainly BNT162b2 and CoronaVac vaccines. We aimed to estimate vaccine effectiveness (VE) to prevent COVID-19 symptomatic cases, hospitalization, critical care admission, and deaths in a cohort of 796,072 insured subjects older than 40 years in northern Colombia, a setting with a high SARS-CoV-2 transmission. We identified individuals vaccinated between March 1st of 2021 and August 15th of 2021. We included symptomatic cases, hospitalizations, critical care admissions, and deaths in patients with confirmed COVID-19 as main outcomes. We calculated VE for each outcome from the hazard ratio in Cox proportionally hazards regressions (adjusted by age, sex, place of residence, diabetes, human immunodeficiency virus, cancer, hypertension, tuberculosis, neurological diseases, and chronic renal disease), with 95% confidence intervals (CI). A total of 719,735 insured participants of 40 and more years were followed. We found 21,545 laboratory-confirmed symptomatic COVID-19 among unvaccinated population, along with 2874 hospitalizations, 1061 critical care admissions, and 1329 deaths, for a rate of 207.2 per million person-days, 27.1 per million person-days, 10.0 per million person-days, and 12.5 per million person-days, respectively. We found CoronaVac was not effective for any outcome in subjects above 80 years old; but for people 40-79 years of age, we found two doses of CoronaVac reduced hospitalization (33.1%; 95% CI, 14.5-47.7), critical care admission (47.2%; 95% CI, 18.5-65.8), and death (55.7%; 95% CI, 32.5-70.0). We found BNT162b2 was effective for all outcomes in the entire population of subjects above 40 years of age, significantly declining for subjects ≥80 years. Two doses of either CoronaVac in population between 40 and 79 years of age, or BNT162b2 among vaccinated above 40 years old significantly reduced deaths of confirmed COVID-19 in a cohort of individuals from Colombia. Vaccine effectiveness for CoronaVac and BNT162b2 declined with increasing age. UK National Institute for Health Research, the European Union's Horizon 2020 research and innovation programme, and the Bill & Melinda Gates Foundation.
Sections du résumé
Background
UNASSIGNED
In February 2021, Colombia began mass vaccination against COVID-19 using mainly BNT162b2 and CoronaVac vaccines. We aimed to estimate vaccine effectiveness (VE) to prevent COVID-19 symptomatic cases, hospitalization, critical care admission, and deaths in a cohort of 796,072 insured subjects older than 40 years in northern Colombia, a setting with a high SARS-CoV-2 transmission.
Methods
UNASSIGNED
We identified individuals vaccinated between March 1st of 2021 and August 15th of 2021. We included symptomatic cases, hospitalizations, critical care admissions, and deaths in patients with confirmed COVID-19 as main outcomes. We calculated VE for each outcome from the hazard ratio in Cox proportionally hazards regressions (adjusted by age, sex, place of residence, diabetes, human immunodeficiency virus, cancer, hypertension, tuberculosis, neurological diseases, and chronic renal disease), with 95% confidence intervals (CI).
Findings
UNASSIGNED
A total of 719,735 insured participants of 40 and more years were followed. We found 21,545 laboratory-confirmed symptomatic COVID-19 among unvaccinated population, along with 2874 hospitalizations, 1061 critical care admissions, and 1329 deaths, for a rate of 207.2 per million person-days, 27.1 per million person-days, 10.0 per million person-days, and 12.5 per million person-days, respectively. We found CoronaVac was not effective for any outcome in subjects above 80 years old; but for people 40-79 years of age, we found two doses of CoronaVac reduced hospitalization (33.1%; 95% CI, 14.5-47.7), critical care admission (47.2%; 95% CI, 18.5-65.8), and death (55.7%; 95% CI, 32.5-70.0). We found BNT162b2 was effective for all outcomes in the entire population of subjects above 40 years of age, significantly declining for subjects ≥80 years.
Interpretation
UNASSIGNED
Two doses of either CoronaVac in population between 40 and 79 years of age, or BNT162b2 among vaccinated above 40 years old significantly reduced deaths of confirmed COVID-19 in a cohort of individuals from Colombia. Vaccine effectiveness for CoronaVac and BNT162b2 declined with increasing age.
Funding
UNASSIGNED
UK National Institute for Health Research, the European Union's Horizon 2020 research and innovation programme, and the Bill & Melinda Gates Foundation.
Identifiants
pubmed: 35791428
doi: 10.1016/j.lana.2022.100296
pii: S2667-193X(22)00113-2
pmc: PMC9246705
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100296Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
No author declares any conflicts of interest.
Références
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Lancet Infect Dis. 2022 Jan;22(1):56-63
pubmed: 34509185
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2021 Dec 16;385(25):2397-2399
pubmed: 34731554
Sci Rep. 2022 May 18;12(1):8269
pubmed: 35585211
NCHS Data Brief. 2017 Oct;(289):1-8
pubmed: 29155682
Lancet Reg Health Am. 2022 Feb;6:100154
pubmed: 34957437
Colomb Med (Cali). 2019 Jun 30;50(2):115-127
pubmed: 31607768
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
BMC Infect Dis. 2022 Mar 30;22(1):273
pubmed: 35351028
Sci Adv. 2022 Feb 18;8(7):eabl3825
pubmed: 35179963
PLoS One. 2021 Aug 5;16(8):e0255343
pubmed: 34351971
Science. 2021 May 28;372(6545):
pubmed: 33906968
Lancet Reg Health Am. 2021 Sep;1:100025
pubmed: 34386791
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Int J Infect Dis. 2021 Dec;113:344-346
pubmed: 34757202
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):396-401
pubmed: 33735160
Lancet Healthy Longev. 2022 Apr;3(4):e242-e252
pubmed: 35340743
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246